PMID- 30172789
OWN - NLM
STAT- MEDLINE
DCOM- 20190213
LR  - 20190215
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 837
DP  - 2018 Oct 15
TI  - 3,4-Methylenedioxymethamphetamine, mephedrone, and beta-phenylethylamine release 
      dopamine from the cytoplasm by means of transporters and keep the concentration 
      high and constant by blocking reuptake.
PG  - 72-80
LID - S0014-2999(18)30500-4 [pii]
LID - 10.1016/j.ejphar.2018.08.037 [doi]
AB  - The addiction-related behavioural effects of drugs of abuse are mediated by the 
      mesocorticolimbic monoamine systems. We investigated the effects of 
      3,4-methylenedioxymethamphetamine (MDMA), mephedrone, beta-phenylethylamine (beta-PEA) 
      methylphenidate (MPH) on dopamine release from mouse perfused nucleus accumbens 
      and prefrontal cortex slices. The fractional release of [(3)H]-dopamine was 
      measured at rest and in response to field stimulation. The distributions of 
      [(3)H]-dopamine and its metabolites were determined using high-pressure liquid 
      chromatography. The effect of drugs on [(3)H]-dopamine uptake was measured in 
      synaptosomal P2 preparations from the frontal cortex and striatum. Similar to 
      MDMA, mephedrone beta-PEA increased the resting release of [(3)H]-dopamine from the 
      nucleus accumbens and prefrontal cortex in a [Ca(2+)](o)-independent manner, and 
      the stimulation-evoked release was also augmented. In contrast, MPH failed to 
      affect the resting release but potentiated the release in response to axonal 
      activity. Similar to dopamine transporter antagonist GBR 12909, mephedrone, MDMA 
      and MPH biphasically inhibited the [(3)H]-dopamine uptake. The administration of 
      GBR 12909 and nisoxetine, or lowering the bath temperature prevented MDMA, 
      mephedrone and beta-PEA from enhancing the resting, cytoplasmic release of 
      [(3)H]-dopamine, indicating the role of transporters in the release process. We 
      conclude that amphetamine-like drugs of abuse and the trace amine beta-PEA 
      excessively increase the [Ca(2+)](o)-independent, non-vesicular release of 
      dopamine from the cytoplasm into the extrasynaptic space and inhibit the 
      high-affinity transporters, thereby maintaining a high ambient, non-synaptic 
      concentration of dopamine that may tonically control the activity of neurons 
      equipped with dopamine receptors and is likely involved in the reinforcing 
      effects and abusive potential of amphetamines.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Zsilla, Gabriella
AU  - Zsilla G
AD  - Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy 
      of Sciences, Budapest, Hungary. Electronic address: zsilla@koki.hu.
FAU - Hegyi, Daniella E
AU  - Hegyi DE
AD  - Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy 
      of Sciences, Budapest, Hungary. Electronic address: dahegyi@gmail.com.
FAU - Baranyi, Maria
AU  - Baranyi M
AD  - Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy 
      of Sciences, Budapest, Hungary. Electronic address: baranyi@koki.hu.
FAU - Vizi, E Sylvester
AU  - Vizi ES
AD  - Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy 
      of Sciences, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, 
      Semmelweis University, Budapest, Hungary. Electronic address: esvizi@koki.mta.hu.
LA  - eng
PT  - Journal Article
DEP - 20180830
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Dopamine Uptake Inhibitors)
RN  - 0 (Phenethylamines)
RN  - 327C7L2BXQ (phenethylamine)
RN  - 44RAL3456C (Methamphetamine)
RN  - 8BA8T27317 (mephedrone)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - SY7Q814VUP (Calcium)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Calcium/physiology
MH  - Cytoplasm/*metabolism
MH  - Dopamine/*metabolism
MH  - Dopamine Plasma Membrane Transport Proteins/*physiology
MH  - Dopamine Uptake Inhibitors/*pharmacology
MH  - Male
MH  - Methamphetamine/*analogs & derivatives/pharmacology
MH  - Mice
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Nucleus Accumbens/metabolism
MH  - Phenethylamines/*pharmacology
MH  - Prefrontal Cortex/metabolism
OTO - NOTNLM
OT  - Dopamine
OT  - MDMA
OT  - Mephedrone
OT  - Methylphenidate
OT  - Release
OT  - beta-phenylethylamine
EDAT- 2018/09/03 06:00
MHDA- 2019/02/14 06:00
CRDT- 2018/09/03 06:00
PHST- 2018/03/28 00:00 [received]
PHST- 2018/08/24 00:00 [revised]
PHST- 2018/08/29 00:00 [accepted]
PHST- 2018/09/03 06:00 [pubmed]
PHST- 2019/02/14 06:00 [medline]
PHST- 2018/09/03 06:00 [entrez]
AID - S0014-2999(18)30500-4 [pii]
AID - 10.1016/j.ejphar.2018.08.037 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2018 Oct 15;837:72-80. doi: 10.1016/j.ejphar.2018.08.037. Epub 
      2018 Aug 30.